DarifenacinM3 receptor antagonist and antimuscarinic agents CAS# 133099-04-4 |
- Cevimeline
Catalog No.:BCC1470
CAS No.:107233-08-9
- Biperiden HCl
Catalog No.:BCC4565
CAS No.:1235-82-1
- Darifenacin HBr
Catalog No.:BCC4567
CAS No.:133099-07-7
- Cevimeline hydrochloride hemihydrate
Catalog No.:BCC1471
CAS No.:153504-70-2
- Umeclidinium bromide
Catalog No.:BCC2022
CAS No.:869113-09-7
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 133099-04-4 | SDF | Download SDF |
| PubChem ID | 72054 | Appearance | Powder |
| Formula | C28H30N2O2 | M.Wt | 426.55 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | UK-88525 | ||
| Solubility | Soluble in DMSO | ||
| Chemical Name | 2-[1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl]-2,2-diphenylacetamide | ||
| SMILES | C1CN(CC1C(C2=CC=CC=C2)(C3=CC=CC=C3)C(=O)N)CCC4=CC5=C(C=C4)OCC5 | ||
| Standard InChIKey | HXGBXQDTNZMWGS-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C28H30N2O2/c29-27(31)28(23-7-3-1-4-8-23,24-9-5-2-6-10-24)25-14-17-30(20-25)16-13-21-11-12-26-22(19-21)15-18-32-26/h1-12,19,25H,13-18,20H2,(H2,29,31) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Darifenacin(UK88525) is a selective M3 muscarinic receptor antagonist with pKi of 8.9.
IC50 value: 8.9 (pKi) [1]
Target: M3 receptor
in vitro: Darifenacin exerts non-parallel rightward displacement of the agonist curve and also significant depression of the maximum response (+)-cis-Dioxolane produced concentration-dependent contraction of the isolated bladder of rat [1]. Darifenacin produces a concentration dependent increase in R123 (P-gp probe) accumulation in MDCK cells. Darifenacin stimulates ATPase activity in P-gp membrane in a clear concentration dependent response manner with an estimated ED50 value of 1.6 μM. Darifenacin (100 nM) shows a significantly greater permeability for darifenacin in the basolateral to apical direction resulting in an efflux ratio in BBMEC monolayers of approximately 2.6 [2].
in vivo: Darifenacin produces dose-dependent inhibition of amplitude of volume-induced bladder contractions(VIBCAMP), producing 35% inhibition at dose of 283.3 nmol/kg and maximal inhibition of approximately 50–55% [1]. Darifenacin (0.1 mg/kg i.v.) reduces bladder afferent activity in both Aδ and C fibers in female Sprague-Dawley rats, the decrease in afferent spikes in C fibers may be more pronounced than that in Aδ fibers [3]. References: | |||||
Darifenacin Dilution Calculator
Darifenacin Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.3444 mL | 11.722 mL | 23.4439 mL | 46.8878 mL | 58.6098 mL |
| 5 mM | 0.4689 mL | 2.3444 mL | 4.6888 mL | 9.3776 mL | 11.722 mL |
| 10 mM | 0.2344 mL | 1.1722 mL | 2.3444 mL | 4.6888 mL | 5.861 mL |
| 50 mM | 0.0469 mL | 0.2344 mL | 0.4689 mL | 0.9378 mL | 1.1722 mL |
| 100 mM | 0.0234 mL | 0.1172 mL | 0.2344 mL | 0.4689 mL | 0.5861 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Darifenacin is a selectivity M3 receptor antagonist and newer antimuscarinic agents. Darifenacin is indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and frequency in adults.
- 3PO
Catalog No.:BCC5616
CAS No.:13309-08-5
- Crassifoline methine
Catalog No.:BCN1793
CAS No.:133084-00-1
- Fmoc-D-Lys(Boc)-OPfp
Catalog No.:BCC3527
CAS No.:133083-36-0
- BIM 23052
Catalog No.:BCC5945
CAS No.:133073-82-2
- ZD 7288
Catalog No.:BCC6884
CAS No.:133059-99-1
- Go 6983
Catalog No.:BCC3705
CAS No.:133053-19-7
- GF 109203X
Catalog No.:BCC3704
CAS No.:133052-90-1
- LY 225910
Catalog No.:BCC6891
CAS No.:133040-77-4
- Ethacrynic acid - d5
Catalog No.:BCC7987
CAS No.:1330052-59-9
- (+)-SK&F 10047 hydrochloride
Catalog No.:BCC6928
CAS No.:133005-41-1
- 13-Epijhanol
Catalog No.:BCN4713
CAS No.:133005-15-9
- Trichlormethiazide
Catalog No.:BCC4872
CAS No.:133-67-5
- Darifenacin HBr
Catalog No.:BCC4567
CAS No.:133099-07-7
- Flutamide
Catalog No.:BCC4364
CAS No.:13311-84-7
- Epimedin B1
Catalog No.:BCN8199
CAS No.:133137-58-3
- GR 73632
Catalog No.:BCC5801
CAS No.:133156-06-6
- Oxypeucedan hydrate
Catalog No.:BCN8372
CAS No.:133164-11-1
- Fmoc-Cit-OH
Catalog No.:BCC3180
CAS No.:133174-15-9
- Fmoc-Thr(Trt)-OH
Catalog No.:BCC3554
CAS No.:133180-01-5
- PI3k-delta inhibitor 1
Catalog No.:BCC1861
CAS No.:1332075-63-4
- AM 92016 hydrochloride
Catalog No.:BCC6825
CAS No.:133229-11-5
- Heliangin
Catalog No.:BCN6487
CAS No.:13323-48-3
- 4-O-Methylbutein
Catalog No.:BCN6677
CAS No.:13323-67-6
- GSK2194069
Catalog No.:BCC8053
CAS No.:1332331-08-4
'Tamsulosin and Darifenacin' Versus 'Tamsulosin Monotherapy' for 'BPH with Accompanying Overactive Bladder'.[Pubmed:26266159]
J Clin Diagn Res. 2015 Jun;9(6):PC08-11.
PURPOSE: To evaluate the efficacy/safety of 'tamsulosin and Darifenacin' (TD) vs. 'tamsulosin and placebo' (TP) for patients with symptomatic benign prostrate hyperplasia (BPH) with accompanying overactive bladder (OAB) symptoms. MATERIALS AND METHODS: This study included symptomatic patients of BPH with one or more of the following OAB symptoms; micturition frequency >8, nocturnal frequency > 2, urgency > 1 per 24 hour between November 2012 and February 2014. After protocol approval by ethics committee and obtaining informed consent, patients were randomly assigned to receive tamsulosin 0.4mg plus placebo (TP) (n=30) or tamsulosin 0.4 mg plus Darifenacin 7.5 mg (TD) (n=30) for 8 weeks. The mean change from baseline in urinary frequency and incontinence episodes/24 hour (primary end points), and nocturnal frequency; mean change in PVR and changes in IPSS (secondary end points) were compared between groups at 0/eight week using voiding diary and ultrasonography. RESULTS: The mean change in frequency, incontinence, nocturnal frequency/24 hour and IPSS (International prostrate symptom score) were (-4.83 vs. -3.93, p=0.023), (-1.50 vs. 1.08, p=0.001), (-2.20 vs. -1.87, p<0.001) and (-7.90 vs. -6.27, p<0.001) in the TD/TP group respectively (significant). Apart from some minor side effects (12 vs. 9) all interventions appeared to be safe and well tolerated. The mean change in the PVR (Postvoid residual) was marginal (+10.84ml and -16.93) and the incidence of urinary retention was 13% and 3% in the TD and TP groups respectively (p=0.35). CONCLUSION: Treatment with tamsulosin and Darifenacin for 8 weeks is an effective and safe treatment modality in select patients of BPH with accompanying OAB symptoms.
Treatment of Overactive Bladder in the Elderly Female: The Case for Trospium, Oxybutynin, Fesoterodine and Darifenacin.[Pubmed:26391900]
Drugs Aging. 2015 Oct;32(10):809-19.
Overactive bladder (OAB) is a common constellation of lower urinary tract storage symptoms that causes a significant impact on a person's quality of life. The elderly may be disproportionally impacted by these symptoms due to concomitant poor mobility, comorbid conditions such as diabetes and heart failure, and polypharmacy. While behavioral modification and pelvic floor muscle training should be considered first-line treatment options, pharmacotherapy remains the backbone of the therapeutic regimen. Trospium, oxybutynin, fesoterodine, and Darifenacin all have unique properties that may confer certain advantages in the elderly population. The hydrophilicity and quaternary amine structure of trospium may limit its ability to cross the blood-brain barrier and thus minimize impact on cognition in the elderly. In its oral form, oxybutynin may have the most significant effect on cognition; however, the transdermal preparations may be favorable in the elderly population due to the ability to avoid first-pass metabolism and its limited antimuscarinic adverse effects. Fesoterodine may be the most extensively studied OAB medication in the elderly population. Darifenacin has a strong affinity for the M3 receptor in the bladder, while having a weak affinity for the M1 receptor commonly found in the brain. It must be noted that all muscarinic receptor antagonists are associated with common adverse effects to some degree, and frequent re-evaluation of the elderly patient is necessary to confirm the proper benefit-to-risk profile.
An evaluation of the efficacy of solifenacin and darifenacin for prevention of catheter related bladder discomfort: a prospective, randomized, placebo controlled, double blind study.[Pubmed:27188787]
Minerva Anestesiol. 2016 May 18. pii: R02Y9999N00A16051801.
BACKGROUND: Urinary catheterization during surgical interventions causes postoperative catheter related bladder discomfort (CRBD). Antimuscarinic agents are the mainstay of treatment for overactive bladder (OAB). As the symptoms of CRBD mimic to OAB, so we designed this study to assess the efficacy of solifenacin and Darifenacin for prevention of CRBD. METHODS: Ninety patients of either sex undergoing elective spine surgery and requiring urinary catheterization were randomly assigned into three groups to receive oral solifenacin 5 mg (Group S), Darifenacin 7.5 mg (Group D) and placebo (Group C) 1 hour prior to induction of anesthesia. Anesthesia technique was identical in all the groups. Catheter related bladder discomfort (CRBD) was evaluated in 4-point scale (1 = no discomfort, 2 = mild, 3 = moderate, 4 = severe), on arrival (0 hour) and at 1, 2, and 6 hours postoperatively. Patients were provided patient-controlled analgesia with fentanyl for postoperative pain relief. RESULTS: There were no significant differences in demographic profile and fentanyl requirements (P >0.05). The prevalence and severity of CRBD were significantly less in the group D and group S compared with the group C at all time intervals (P <0.05). CONCLUSION: Pretreatment with oral solifenacin or Darifenacin reduces catheter-related bladder discomfort with no clinically relevant significant side effects.
Evaluation of the efficacy of solifenacin and darifenacin for prevention of catheter-related bladder discomfort: a prospective, randomized, placebo-controlled, double-blind study.[Pubmed:27607187]
Minerva Anestesiol. 2016 Aug;82(8):867-73.
BACKGROUND: Urinary catheterization during surgical interventions causes postoperative catheter-related bladder discomfort (CRBD). Antimuscarinic agents are the mainstay of treatment for overactive bladder (OAB). As the symptoms of CRBD mimic to OAB, so we designed this study to assess the efficacy of solifenacin and Darifenacin for prevention of CRBD. METHODS: Ninety patients of either sex undergoing elective spine surgery and requiring urinary catheterization were randomly assigned into three groups to receive oral solifenacin 5 mg (Group S), Darifenacin 7.5 mg (Group D) and placebo (Group C) 1 hour prior to induction of anesthesia. Anesthesia technique was identical in all the groups. Catheter-related bladder discomfort (CRBD) was evaluated in 4-point scale (1 = no discomfort, 2 = mild discomfort, 3 = moderate discomfort, 4 = severe discomfort), on arrival (0 hour) and at 1, 2, and 6 hours postoperatively. Patients were provided patient-controlled analgesia with fentanyl for postoperative pain relief. RESULTS: There were no significant differences in demographic profile and fentanyl requirements (P>0.05). The prevalence and severity of CRBD were significantly less in the group D and group S compared with the group C at all time intervals (P<0.05). CONCLUSIONS: Pretreatment with oral solifenacin or Darifenacin reduces catheter-related bladder discomfort with no clinically relevant significant side effects.
